González, Sara

Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. [electronic resource] - Brain research Feb 2006 - 209-19 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

0006-8993

10.1016/j.brainres.2005.12.014 doi


Adrenergic Agents--toxicity
Analysis of Variance
Animals
Autoradiography--methods
Brain--drug effects
Brain Chemistry--drug effects
Chromatography, High Pressure Liquid--methods
Disease Models, Animal
Dopamine--metabolism
Dose-Response Relationship, Drug
Drug Interactions
Electrochemistry--methods
Gene Expression--drug effects
Glutamic Acid--metabolism
In Situ Hybridization--methods
Injections, Intraventricular--methods
Male
Motor Activity--drug effects
Oxidopamine--toxicity
Parkinson Disease--drug therapy
Piperidines--therapeutic use
Protein Binding--drug effects
Pyrazoles--therapeutic use
RNA, Messenger--metabolism
Rats
Rats, Sprague-Dawley
Reaction Time--drug effects
Receptor, Cannabinoid, CB1--antagonists & inhibitors
Rimonabant
Rotarod Performance Test--methods
Superoxide Dismutase--genetics
Superoxide Dismutase-1
Tyrosine 3-Monooxygenase--genetics
gamma-Aminobutyric Acid--metabolism